Maynard Um
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Raised to $32 at RBC Capital
-
-
-
-
-
-
-
4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 25c
-
-
-
-
-
-
-
BMO Capital Downgrades 4D Molecular Therapeutics (FDMT) to Market Perform
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
-
-
-
-
-
-
-
2Q24 U.S. biotech earnings preview
-
-
405,442 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

